|
1
|
Sydorak RM and Applebaum H: Soft Tissue
TumorsFundamentals of Pediatric Surgery. Mattei P: Springer-Verlag;
New York, NY: pp. 755–760. 2011, View Article : Google Scholar
|
|
2
|
Li W: The new concept of cancer supportive
treatment. Electronic Journal of Metabolism and Nutrition of
Cancer. 1:2014.
|
|
3
|
Horiot JC: At last-progress in the
assessment of the adverse effects of cancer treatments. Lancet
Oncol. 8:568–570. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barrett PT, Petrides K, Eysenck SB and
Eysenck HJ: The Eysenck personality questionnaire: An examination
of the factorial similarity of PE, N and L across 34 countries.
Personality Individual Differences. 25:805–819. 1998. View Article : Google Scholar
|
|
5
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaffaroni N and Daidone MG: Survivin
expression and resistance to anticancer treatments: Perspectives
for new therapeutic interventions. Drug Resistance Updates.
5:65–72. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kong LJ, Zhao J and Fan WW: Survivin and
Tumor Angiogenesis. Zhong Liu Xue Za Zhi. 15:950–952. 2009.(In
Chinese).
|
|
8
|
Suzuki A, Hayashida M, Ito T, Kawano H,
Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell
cycle entry by the competitive interaction with Cdk4/p16 (INK4a)
and Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mesri M, Morales-Ruiz M, Ackermann EJ,
Bennett CF, Pober JS, Sessa WC and Altieri DC: Suppression of
vascular endothelial growth factor-mediated endothelial cell
protection by survivin targeting. Am J Pathol. 158:1757–1765. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kayaselcuk F, Nursal T, Polat A, Noyan T,
Yildirim S, Tarim A and Seydaoglu G: Expresion of survivin, Bcl-2,
P53 and bax in breast carcioma and ductal intraepithelial neoplasia
(DIN 1a). J Exp Clin Cancer Res. 23:105–112. 2004.PubMed/NCBI
|
|
12
|
Ryan BM, O'Donovan N and Duffy MJ:
Survivin: A new target for anti-cancer therapy. Cancer Treat Rev.
35:553–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ and
Lin TY: Effects and mechanism of downregulation of survivin
expression by RNA interference on proliferation and apoptosis of
lung cancer cells. Mol Med Rep. 5:917–922. 2012.PubMed/NCBI
|
|
15
|
Baker B, Eldrup A, Manoharan M, et al:
RNA-induced silencing complexes; RNA interference; gene expression
inhibition US patent 10/700,884. October 4–2003, issued February
17. 2005
|
|
16
|
Aliabadi H Montazeri, Landry B, Mahdipoor
P and Uludag H: Induction of apoptosis by survivin silencing
through siRNA delivery in a human breast cancer cell line. Mol
Pharm. 8:1821–1830. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mirandola P, Sponzilli I, Gobbi G,
Marmiroli S, Rinaldi L, Binazzi R, Piccari GG, Ramazzotti G,
Gaboardi GC, Cocco L and Vitale M: Anticancer agents sensitize
osteosarcoma cells to TNF-related apoptosis-inducing ligand
downmodulating IAP family proteins. Int J Oncol. 28:127–133.
2006.PubMed/NCBI
|
|
19
|
Stewart B and Wild C: World cancer report
2014. International Agency for Research on Cancer; Lyon: 2014
|
|
20
|
Organization WH: ES Fact sheet 310: Top
causes of death. Centro De Prensa. 2014.
|
|
21
|
Arnold LD, Ji QS, Buck E, Haley JD and
Mulvihill MJ: Combination cancer therapy U.S. Patent 8,575,164.
2013
|
|
22
|
Yang Y and Huang S: Discuss the strengths
and weaknesses between tumour biotherapy and chemoradiotherapy.
Medical Information. 24:3503–3504. 2011.
|
|
23
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reed JC: Dysregulation of apoptosis in
cancer. J Clin Oncol. 17:2941–2953. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiou SK, Jones MK and Tarnawski AS:
Survivin-an anti-apoptosis protein: Its biological roles and
implications for cancer and beyond. Med Sci Monit. 9:PI25–PI29.
2003.PubMed/NCBI
|
|
26
|
Merritt WM, Bar-Eli M and Sood AK: The
dicey role of Dicer: Implications for RNAi therapy. Cancer Res.
70:2571–2574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Semple SC, Akinc A, Chen J, Sandhu AP, Mui
BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, et al:
Rational design of cationic lipids for siRNA delivery. Nat
Biotechnol. 28:172–176. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Medarova Z, Pham W, Farrar C, Petkova V
and Moore A: In vivo imaging of siRNA delivery and silencing in
tumors. Nat Med. 13:372–377. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wenying Z, Zhaoning J, Zhimin Y, Dongyun C
and Lili S: Survivin siRNA inhibits gastric cancer in nude mice.
Cell Biochem Biophys. 62:337–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rödel F, Hoffmann J, Distel L, Herrmann M,
Noisternig T, Papadopoulos T, Sauer R and Rödel C: Survivin as a
radioresistance factor, and prognostic and therapeutic target for
radiotherapy in rectal cancer. Cancer Res. 65:4881–4887. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ning S, Fuessel S, Kotzsch M, Kraemer K,
Kappler M, Schmidt U, Taubert H, Wirth MP and Meye A:
siRNA-mediated down-regulation of survivin inhibits bladder cancer
cell growth. Int J Oncol. 25:1065–1071. 2004.PubMed/NCBI
|
|
32
|
Endoh A, Asanuma K, Moriai R, Yamada M,
Koyanagi Y, Sato T, Yagihasi A, Nakamura M, Kobayashi D and
Watanabe N: Expression of survivin mRNA in CD34-positive cells.
Clin Chim Acta. 306:149–151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee GH, Joo YE, Koh YS, Chung IJ, Park YK,
Lee JH, Kim HS, Choi SK, Rew JS, Park CS and Kim SJ: Expression of
survivin in gastric cancer and its relationship with tumor
angiogenesis. Eur J Gastroenterol Hepatol. 18:957–963. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smith SD, Wheeler MA, Plescia J, Colberg
JW, Weiss RM and Altieri DC: Urine detection of survivin and
diagnosis of bladder cancer. JAMA. 285:324–328. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yao X, Liu F, Qi X, Wu B, Yin HL, Ma HH,
Shi QL, Zhou XJ and Li JS: Expression of survivin in human gastric
adenocarcinomas: Correlation with proliferation and apoptosis.
Zhonghua Wai Ke Za Zhi. 42:145–148. 2004.(In Chinese). PubMed/NCBI
|
